CGA and neuroendocrine neoplasm: It is therefore possible that increased levels of circulating CgA and its fragments, as may occur in the subpopulation of cancer patients with non‐neuroendocrine tumors, can reduce drug delivery to tumor cells, particularly when they are combined with NGR‐TNF.